Gilead Sciences Inc (GILDm)

Currency in ARS
59,425.000
-75.000(-0.13%)
Closed·
Advertisement
Trading near 52-week High
GILDm is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
55,500.00060,500.000
52 wk Range
38,225.00060,500.000
Key Statistics
Bid/Ask
46,700.00 / 60,000.00
Prev. Close
59,500
Open
60,000
Day's Range
55,500-60,500
52 wk Range
38,225-60,500
Volume
691
Average Volume (3m)
1.34K
1-Year Change
53.9508%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GILDm Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Prominent player in the Biotechnology industry

Gilead Sciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell

Earnings

Latest Release
04/08/2026
EPS / Forecast
-8.45 / --
Revenue / Forecast
7.8B / --
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -2.62%
Dividend Yield
2.08%
Industry Median 2.00%
Annualised payout
1,240.45
Paid quarterly
5-Years Growth
+2.98%
Growth Streak

Compare GILDm to Peers and Sector

Metrics to compare
GILDm
Peers
Sector
Relationship
P/E Ratio
−57.4x−3.9x−0.4x
PEG Ratio
0.380.020.00
Price/Book
15.7x1.3x2.6x
Price / LTM Sales
6.1x1.1x3.1x
Upside (Analyst Target)
-14.2%49.0%
Fair Value Upside
Unlock−2.2%7.1%Unlock

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Employees
17000
Market
Argentina

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
681.07M54.93%39.89T
Other Institutional Investors
448.06M36.14%26.25T
Public Companies & Retail Investors
110.82M8.94%6.49T
Total
1.24B100.00%72.63T

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.9.83%121,844,1087,137,018,626
Vanguard Capital Management, LLC7.10%88,063,7615,158,334,801

People Also Watch

304,725.00
MUm
+2.48%
24,560.00
IBMm
+0.16%
15,040.00
AVGOm
-0.33%
77,475.00
ORCLm
+3.44%
28,400.00
MAm
+1.28%

FAQ

What Is the Gilead Sciences (Buenos Aires: GILDm) Share Price Today?

The Gilead Sciences stock price today is 59,425.000 ARS.

What Stock Exchange Does Gilead Sciences (GILDm) Trade On?

Gilead Sciences is listed and trades on the Buenos Aires Stock Exchange.

What Is the Ticker (Stock Symbol) for Gilead Sciences?

The stock symbol (also called a 'ticker') for Gilead Sciences is "GILDm."

Does Gilead Sciences Pay Dividends? What’s The Current GILDm Dividend Yield?

Yes, GILDm Pays Dividends to its Shareholders. The current Gilead Sciences dividend yield is 2.08%.

What Is the Current Gilead Sciences Market Capitalisation?

As of today, Gilead Sciences (Buenos Aires: GILDm) market cap is 280.840T ARS.

What Is Gilead Sciences's (GILDm) Earnings Per Share (TTM)?

The Gilead Sciences EPS is currently -2.615 (Trailing Twelve Months).

Is GILDm a Buy or Sell From a Technical Analyst Perspective?

Based on today's Gilead Sciences moving averages and other technical indicators, the daily buy/sell signal for GILDm stock is Strong Buy.

How Many Times Has Gilead Sciences Stock Split?

Gilead Sciences has split 0 times. (See the GILDm stock split history page for full effective split date and price information.)

How Many Employees Does Gilead Sciences Have?

Gilead Sciences has 17000 employees, based on their latest Companies House report.

What is the current trading status of Gilead Sciences (Buenos Aires: GILDm)?

As of 03/09/2026, Gilead Sciences (GILDm) is trading at a share price of 59,425.000 ARS, with a previous close of 59,500.000 ARS. The stock has fluctuated within a day range of 55,500.000 ARS to 60,500.000 ARS, while its 52-week range spans from 38,225.000 ARS to 60,500.000 ARS.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.